NCT00003091View on ClinicalTrials.gov

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 1996

Primary Completion Date

January 31, 2000

Study Completion Date

January 31, 2000

Conditions
Kidney CancerMelanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant interferon alfa

Trial Locations (4)

37901

Baptist Regional Cancer Center - Knoxville, Knoxville

47402

Bloomington Hospital, Bloomington

77802

St. Joseph Regional Cancer Center, Bryan

92658

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
collaborator

Cancer Biotherapy Research Group

OTHER

lead

Hoag Memorial Hospital Presbyterian

OTHER

NCT00003091 - High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma | Biotech Hunter | Biotech Hunter